nicotine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1920 54-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicotine
  • L-Nicotine
  • (S)-Nicotine
  • (-)-Nicotine
  • nicotine bitartrate anhydrous
  • nicotine polacrilex
Devices or delivery systems used to aid in ending a TOBACCO habit.
  • Molecular weight: 162.24
  • Formula: C10H14N2
  • CLOGP: 0.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 16.13
  • ALOGS: -0.24
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg Chewing gum
60 mg Inhal
30 mg N
30 mg SL
14 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 16.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.52 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.95 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 1991 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 560.73 13.57 106 15167 549 50589302
Macular degeneration 422.22 13.57 160 15113 14228 50575623
Drug withdrawal syndrome neonatal 283.83 13.57 73 15200 1768 50588083
Drug dependence 255.68 13.57 123 15150 19636 50570215
Incorrect product administration duration 211.58 13.57 86 15187 9189 50580662
Premature delivery 206.55 13.57 113 15160 23550 50566301
Foetal exposure during pregnancy 204.49 13.57 118 15155 27241 50562610
Product adhesion issue 185.59 13.57 64 15209 4328 50585523
Overdose 169.18 13.57 178 15095 99549 50490302
Maternal exposure during pregnancy 127.79 13.57 196 15077 159582 50430269
Myocardial stunning 100.71 13.57 20 15253 139 50589712
Intentional product misuse 85.57 13.57 87 15186 46647 50543204
Application site erythema 83.09 13.57 36 15237 4502 50585349
Jaundice neonatal 81.75 13.57 23 15250 788 50589063
Accidental overdose 80.59 13.57 58 15215 19475 50570376
Dependence 74.10 13.57 26 15247 1849 50588002
Application site pruritus 72.71 13.57 31 15242 3728 50586123
Drug abuse 69.57 13.57 88 15185 59758 50530093
Necrosis ischaemic 68.62 13.57 20 15253 779 50589072
Product quality issue 66.85 13.57 63 15210 30795 50559056
Rhesus incompatibility 66.69 13.57 13 15260 81 50589770
Poor feeding infant 64.83 13.57 15 15258 229 50589622
Premature baby 63.46 13.57 49 15224 18288 50571563
Exposure during pregnancy 63.12 13.57 123 15150 120892 50468959
Pneumonia streptococcal 58.33 13.57 21 15252 1610 50588241
Oligohydramnios 54.43 13.57 29 15244 5721 50584130
Beta haemolytic streptococcal infection 52.35 13.57 20 15253 1810 50588041
Maternal exposure during breast feeding 50.53 13.57 23 15250 3231 50586620
Rib deformity 47.91 13.57 11 15262 162 50589689
Tobacco abuse 47.06 13.57 14 15259 586 50589265
Chronic obstructive pulmonary disease 46.07 13.57 68 15205 53367 50536484
Low birth weight baby 45.59 13.57 26 15247 5855 50583996
Exposure via breast milk 40.42 13.57 16 15257 1592 50588259
Treatment noncompliance 39.32 13.57 47 15226 30103 50559748
Rheumatoid arthritis 39.06 13.57 7 15266 202543 50387308
Application site rash 37.67 13.57 17 15256 2340 50587511
Application site reaction 37.14 13.57 12 15261 662 50589189
Congenital tricuspid valve incompetence 36.51 13.57 8 15265 94 50589757
Anxiety 35.47 13.57 126 15147 177480 50412371
Congenital pulmonary hypertension 34.27 13.57 7 15266 57 50589794
Alopecia 32.07 13.57 17 15256 245030 50344821
Arthropathy 31.44 13.57 5 15268 157901 50431950
Substance abuse 31.34 13.57 18 15255 4106 50585745
Reversible cerebral vasoconstriction syndrome 29.85 13.57 14 15259 2105 50587746
Premature separation of placenta 29.70 13.57 13 15260 1665 50588186
Developmental hip dysplasia 29.52 13.57 12 15261 1279 50588572
Reversible airways obstruction 28.65 13.57 11 15262 1009 50588842
Nasal obstruction 28.48 13.57 11 15262 1025 50588826
Caesarean section 28.39 13.57 29 15244 15610 50574241
Toxicity to various agents 28.30 13.57 133 15140 212366 50377485
Agitation neonatal 27.90 13.57 9 15264 494 50589357
Maternal drugs affecting foetus 27.89 13.57 18 15255 5059 50584792
Dysmetropsia 27.04 13.57 6 15267 75 50589776
Application site irritation 26.93 13.57 12 15261 1603 50588248
Throat clearing 26.93 13.57 11 15262 1187 50588664
Loss of proprioception 26.73 13.57 8 15265 342 50589509
Joint swelling 26.66 13.57 21 15252 245265 50344586
Axonal neuropathy 26.08 13.57 10 15263 914 50588937
Fatigue 25.27 13.57 119 15154 707482 49882369
Xanthogranuloma 24.76 13.57 4 15269 6 50589845
Systemic lupus erythematosus 24.75 13.57 6 15267 140616 50449235
Off label use 24.00 13.57 69 15204 474357 50115494
Treatment failure 23.97 13.57 6 15267 137631 50452220
Application site swelling 23.95 13.57 8 15265 490 50589361
Abnormal dreams 23.93 13.57 21 15252 9356 50580495
Therapeutic product effect decreased 23.56 13.57 6 15267 136044 50453807
Drug intolerance 23.50 13.57 19 15254 219085 50370766
Symphysiolysis 23.14 13.57 4 15269 11 50589840
Arthralgia 22.77 13.57 63 15210 438639 50151212
Application site dermatitis 22.32 13.57 6 15267 173 50589678
Premature labour 22.15 13.57 22 15251 11454 50578397
Abortion induced 22.01 13.57 20 15253 9324 50580527
Irritability 21.42 13.57 34 15239 28392 50561459
Pain 20.25 13.57 98 15175 578805 50011046
Respiratory failure 20.19 13.57 67 15206 91114 50498737
Sneezing 20.15 13.57 23 15250 14021 50575830
Contraindicated product administered 19.97 13.57 10 15263 148948 50440903
Cardiac death 19.89 13.57 7 15266 502 50589349
False positive investigation result 19.68 13.57 7 15266 518 50589333
Application site vesicles 19.23 13.57 9 15264 1346 50588505
Sputum purulent 18.81 13.57 8 15265 955 50588896
Drug screen positive 18.53 13.57 12 15261 3390 50586461
Pre-eclampsia 18.52 13.57 17 15256 8027 50581824
Suicidal ideation 18.34 13.57 47 15226 55338 50534513
Oophoritis 18.18 13.57 4 15269 48 50589803
Prinzmetal angina 17.67 13.57 7 15266 698 50589153
Full blood count abnormal 17.66 13.57 28 15245 23360 50566491
Nightmare 17.64 13.57 23 15250 16063 50573788
Application site pain 17.33 13.57 12 15261 3786 50586065
Infection 17.32 13.57 16 15257 172938 50416913
Megacolon 17.27 13.57 9 15264 1697 50588154
Secondary immunodeficiency 17.20 13.57 8 15265 1180 50588671
Application site burn 17.02 13.57 7 15266 769 50589082
Selective eating disorder 16.66 13.57 9 15264 1823 50588028
Loss of consciousness 16.66 13.57 69 15204 104284 50485567
Application site scar 16.46 13.57 5 15268 225 50589626
Withdrawal syndrome 16.04 13.57 23 15250 17567 50572284
Tobacco poisoning 15.78 13.57 4 15269 91 50589760
Completed suicide 15.70 13.57 80 15193 131809 50458042
Drug abuser 15.47 13.57 10 15263 2818 50587033
Swelling 15.38 13.57 23 15250 200849 50389002
Musculoskeletal stiffness 15.25 13.57 10 15263 128471 50461380
Foetal growth restriction 15.25 13.57 14 15259 6613 50583238
Glossodynia 15.12 13.57 8 15265 115561 50474290
Schizoaffective disorder 15.10 13.57 9 15264 2197 50587654
Patent ductus arteriosus 14.97 13.57 11 15262 3809 50586042
Discomfort 14.94 13.57 7 15266 108373 50481478
Chest X-ray abnormal 14.80 13.57 11 15262 3874 50585977
Hepatitis C 14.57 13.57 12 15261 4905 50584946
Tobacco interaction 14.52 13.57 3 15270 26 50589825
Rhinitis 14.36 13.57 15 15258 8286 50581565
Wound 14.33 13.57 7 15266 105787 50484064
Nervousness 14.25 13.57 28 15245 27623 50562228
Plethysmography 13.87 13.57 3 15270 33 50589818
Foetal distress syndrome 13.85 13.57 7 15266 1238 50588613
Abdominal discomfort 13.75 13.57 31 15242 231610 50358241
Drug withdrawal syndrome 13.66 13.57 26 15247 25055 50564796

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 368.21 13.62 75 12355 412 29561685
Drug withdrawal syndrome neonatal 293.06 13.62 92 12338 3303 29558794
Drug dependence 273.37 13.62 146 12284 20835 29541262
Incorrect product administration duration 222.44 13.62 78 12352 3963 29558134
Foetal exposure during pregnancy 199.52 13.62 142 12288 33725 29528372
Intentional product misuse 160.91 13.62 126 12304 34535 29527562
Accidental overdose 135.12 13.62 87 12343 17506 29544591
Overdose 132.09 13.62 165 12265 79654 29482443
Product adhesion issue 119.18 13.62 38 12392 1433 29560664
Maternal exposure during breast feeding 102.57 13.62 34 12396 1452 29560645
Premature baby 96.02 13.62 70 12360 17210 29544887
Dependence 76.74 13.62 25 12405 1010 29561087
Low birth weight baby 74.92 13.62 42 12388 6566 29555531
Alcohol abuse 64.46 13.62 33 12397 4300 29557797
Jaundice neonatal 64.36 13.62 23 12407 1233 29560864
Foetal disorder 62.49 13.62 20 12410 763 29561334
Exposure via breast milk 57.43 13.62 23 12407 1689 29560408
Neutropenia neonatal 53.33 13.62 17 12413 640 29561457
Toxicity to various agents 52.33 13.62 176 12254 173485 29388612
Tobacco poisoning 52.16 13.62 9 12421 15 29562082
Drug screen positive 48.15 13.62 26 12404 3775 29558322
Drug abuser 47.99 13.62 26 12404 3801 29558296
Poor feeding infant 46.34 13.62 14 12416 440 29561657
Tremor neonatal 44.70 13.62 13 12417 357 29561740
Alcohol interaction 44.35 13.62 22 12408 2681 29559416
Body temperature abnormal 36.87 13.62 12 12418 483 29561614
Breech presentation 36.02 13.62 9 12421 136 29561961
Foetal distress syndrome 35.52 13.62 14 12416 985 29561112
Application site pruritus 35.28 13.62 15 12415 1282 29560815
Schizophrenia 35.10 13.62 26 12404 6539 29555558
Agitation neonatal 34.77 13.62 14 12416 1042 29561055
Substance abuse 34.33 13.62 26 12404 6761 29555336
Tobacco abuse 31.18 13.62 10 12420 384 29561713
Drug use disorder 28.93 13.62 18 12412 3404 29558693
Withdrawal syndrome 28.92 13.62 29 12401 10963 29551134
Application site erythema 28.39 13.62 15 12415 2084 29560013
Laryngeal dysplasia 27.10 13.62 4 12426 0 29562097
Finnegan score increased 26.95 13.62 5 12425 15 29562082
Drug abuse 26.71 13.62 84 12346 79799 29482298
Application site reaction 26.69 13.62 9 12421 405 29561692
Product quality issue 26.42 13.62 33 12397 15862 29546235
Off label use 25.85 13.62 55 12375 300745 29261352
Regurgitation 25.56 13.62 12 12418 1295 29560802
Infant irritability 25.27 13.62 5 12425 23 29562074
Venolymphatic malformation 25.10 13.62 5 12425 24 29562073
Drug withdrawal syndrome 24.71 13.62 34 12396 17950 29544147
Tobacco user 24.67 13.62 9 12421 512 29561585
Tachycardia 23.16 13.62 75 12355 72335 29489762
Oropharyngeal discomfort 23.03 13.62 14 12416 2542 29559555
Treatment noncompliance 22.26 13.62 38 12392 24189 29537908
Vitamin B12 deficiency 22.23 13.62 15 12415 3256 29558841
Application site rash 21.32 13.62 9 12421 755 29561342
Renal hypoplasia 20.93 13.62 5 12425 62 29562035
Diarrhoea 20.23 13.62 72 12358 332626 29229471
Infective exacerbation of chronic obstructive airways disease 20.10 13.62 11 12419 1639 29560458
Acne infantile 19.92 13.62 5 12425 77 29562020
Application site scar 19.47 13.62 4 12426 23 29562074
Floppy infant 18.33 13.62 5 12425 108 29561989
Renal impairment 17.78 13.62 6 12424 81327 29480770
Pulmonary valve stenosis congenital 17.31 13.62 5 12425 134 29561963
Application site vesicles 17.21 13.62 7 12423 535 29561562
Euphoric mood 17.05 13.62 15 12415 4810 29557287
Weight decrease neonatal 16.69 13.62 6 12424 327 29561770
Breathing-related sleep disorder 16.31 13.62 5 12425 165 29561932
Myoclonic epilepsy 16.19 13.62 8 12422 967 29561130
Insomnia 16.17 13.62 77 12353 88684 29473413
Emphysema 16.03 13.62 19 12411 8652 29553445
Neonatal hypoxia 15.87 13.62 6 12424 377 29561720
Palpitations 15.52 13.62 39 12391 32565 29529532
Anxiety 15.51 13.62 74 12356 85291 29476806
Antipsychotic drug level increased 15.47 13.62 12 12418 3231 29558866
Necrotising ulcerative gingivostomatitis 15.41 13.62 4 12426 71 29562026
Application site urticaria 15.35 13.62 4 12426 72 29562025
Hypersensitivity 15.31 13.62 53 12377 52850 29509247
Eructation 15.26 13.62 13 12417 3993 29558104
Application site discolouration 14.96 13.62 5 12425 219 29561878
Nightmare 14.81 13.62 21 12409 11396 29550701
Drug tolerance increased 14.77 13.62 6 12424 457 29561640
Application site pain 14.62 13.62 9 12421 1670 29560427
Neonatal disorder 14.56 13.62 7 12423 796 29561301
Death 14.24 13.62 85 12345 341999 29220098
Potentiating drug interaction 14.11 13.62 13 12417 4425 29557672
Knee deformity 13.66 13.62 6 12424 555 29561542

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 570.18 12.12 113 21193 701 64476725
Drug dependence 481.29 12.12 230 21076 33082 64444344
Incorrect product administration duration 343.15 12.12 127 21179 9631 64467795
Overdose 244.90 12.12 282 21024 159284 64318142
Accidental overdose 221.45 12.12 138 21168 33419 64444007
Intentional product misuse 155.45 12.12 153 21153 72142 64405284
Application site erythema 98.19 12.12 42 21264 4647 64472779
Myocardial stunning 95.57 12.12 20 21286 168 64477258
Application site pruritus 92.02 12.12 37 21269 3502 64473924
Product adhesion issue 86.39 12.12 32 21274 2427 64474999
Drug abuse 78.89 12.12 150 21156 132224 64345202
Toxicity to various agents 75.20 12.12 277 21029 363236 64114190
Alcohol abuse 71.49 12.12 34 21272 4818 64472608
Substance abuse 65.80 12.12 40 21266 9252 64468174
Necrosis ischaemic 62.75 12.12 20 21286 963 64476463
Drug abuser 59.99 12.12 32 21274 5776 64471650
Beta haemolytic streptococcal infection 53.42 12.12 21 21285 1873 64475553
Product quality issue 53.00 12.12 57 21249 29742 64447684
Pneumonia streptococcal 52.11 12.12 22 21284 2356 64475070
Application site reaction 51.69 12.12 16 21290 699 64476727
Tobacco poisoning 51.30 12.12 11 21295 105 64477321
Dependence 50.79 12.12 21 21285 2134 64475292
Application site rash 45.92 12.12 19 21287 1935 64475491
Chronic obstructive pulmonary disease 44.13 12.12 82 21224 70966 64406460
Premature delivery 43.01 12.12 41 21265 18548 64458878
Alcohol interaction 41.98 12.12 23 21283 4378 64473048
Rheumatoid arthritis 39.90 12.12 4 21302 164290 64313136
Application site irritation 39.33 12.12 16 21290 1560 64475866
Rib deformity 39.29 12.12 9 21297 119 64477307
Off label use 37.86 12.12 97 21209 632709 63844717
Tobacco abuse 37.35 12.12 13 21293 823 64476603
Anxiety 37.32 12.12 149 21157 202500 64274926
Application site pain 37.23 12.12 21 21285 4227 64473199
Withdrawal syndrome 36.71 12.12 42 21264 23450 64453976
Application site scar 35.62 12.12 9 21297 184 64477242
Drug use disorder 35.19 12.12 23 21283 6031 64471395
Drug screen positive 33.87 12.12 22 21284 5707 64471719
Treatment noncompliance 33.25 12.12 55 21251 43427 64433999
Drug withdrawal syndrome 33.04 12.12 46 21260 31245 64446181
Drug intolerance 32.12 12.12 11 21295 187981 64289445
Loss of consciousness 31.35 12.12 114 21192 148251 64329175
Euphoric mood 31.07 12.12 22 21284 6569 64470857
Drug ineffective 30.88 12.12 158 21148 840089 63637337
Reversible cerebral vasoconstriction syndrome 30.25 12.12 15 21291 2327 64475099
Schizoaffective disorder 29.27 12.12 13 21293 1574 64475852
Schizophrenia 28.47 12.12 26 21280 11142 64466284
Maternal exposure during pregnancy 27.74 12.12 82 21224 95802 64381624
Body temperature abnormal 26.02 12.12 12 21294 1586 64475840
Tachycardia 25.94 12.12 108 21198 149471 64327955
Maternal drugs affecting foetus 25.86 12.12 12 21294 1608 64475818
Dysmetropsia 25.81 12.12 6 21300 85 64477341
Therapeutic product effect decreased 25.12 12.12 4 21302 115347 64362079
Application site vesicles 24.93 12.12 11 21295 1311 64476115
Throat clearing 24.80 12.12 11 21295 1327 64476099
Application site urticaria 24.39 12.12 7 21299 235 64477191
Exposure during pregnancy 23.98 12.12 68 21238 77607 64399819
Nightmare 23.88 12.12 32 21274 20961 64456465
Regurgitation 22.86 12.12 12 21294 2097 64475329
Emphysema 21.72 12.12 25 21281 14044 64463382
Alopecia 21.68 12.12 14 21292 165676 64311750
Unresponsive to stimuli 21.66 12.12 50 21256 50343 64427083
Application site dermatitis 21.58 12.12 6 21300 179 64477247
Mental status changes 21.33 12.12 56 21250 61106 64416320
Renal impairment 21.23 12.12 9 21297 135008 64342418
Infective exacerbation of chronic obstructive airways disease 21.23 12.12 12 21294 2426 64475000
Loss of proprioception 20.79 12.12 8 21298 674 64476752
Vitamin B12 deficiency 20.70 12.12 16 21290 5456 64471970
Application site discolouration 20.36 12.12 8 21298 712 64476714
Diarrhoea 20.16 12.12 148 21158 722556 63754870
Reversible airways obstruction 19.96 12.12 9 21297 1129 64476297
Arteriosclerosis coronary artery 19.74 12.12 25 21281 15504 64461922
Pulmonary oedema 19.70 12.12 64 21242 78610 64398816
Axonal neuropathy 19.40 12.12 10 21296 1682 64475744
Arthropathy 19.12 12.12 8 21298 120959 64356467
Oropharyngeal discomfort 18.89 12.12 15 21291 5320 64472106
Oophoritis 18.77 12.12 4 21302 37 64477389
Tobacco withdrawal symptoms 18.51 12.12 3 21303 4 64477422
Nasal obstruction 18.43 12.12 9 21297 1350 64476076
Joint swelling 18.03 12.12 27 21279 215355 64262071
Arthralgia 18.02 12.12 80 21226 442180 64035246
Fatigue 17.82 12.12 160 21146 748570 63728856
Application site swelling 17.69 12.12 7 21299 635 64476791
Derealisation 17.62 12.12 9 21297 1486 64475940
Disease progression 17.18 12.12 13 21293 141667 64335759
Palpitations 16.99 12.12 74 21232 104414 64373012
Nervousness 16.97 12.12 33 21273 29523 64447903
Tobacco interaction 16.87 12.12 4 21302 62 64477364
Breathing-related sleep disorder 16.65 12.12 5 21301 197 64477229
Chest pain 16.62 12.12 134 21172 235846 64241580
Xanthogranuloma 16.58 12.12 4 21302 67 64477359
Suicidal ideation 16.54 12.12 54 21252 66488 64410938
Hepatocellular injury 16.37 12.12 42 21264 45193 64432233
Foetal distress syndrome 16.31 12.12 6 21300 446 64476980
False positive investigation result 16.19 12.12 7 21299 794 64476632
Poor quality product administered 15.78 12.12 11 21295 3204 64474222
Potentiating drug interaction 15.71 12.12 16 21290 7836 64469590
Cardiac death 15.67 12.12 8 21298 1320 64476106
Infection 15.65 12.12 23 21283 184857 64292569
Intentional overdose 15.63 12.12 65 21241 89879 64387547
Irritability 15.29 12.12 36 21270 36710 64440716
Pain 14.63 12.12 115 21191 553396 63924030
Abortion induced 14.61 12.12 14 21292 6374 64471052
Mental disorder 14.54 12.12 29 21277 26416 64451010
Accidental death 14.33 12.12 11 21295 3714 64473712
Premature labour 14.30 12.12 15 21291 7605 64469821
Myoclonic epilepsy 14.23 12.12 8 21298 1600 64475826
Depression 13.96 12.12 106 21200 183185 64294241
Premature separation of placenta 13.81 12.12 7 21299 1137 64476289
Plethysmography 13.60 12.12 3 21303 33 64477393
Non-small cell lung cancer stage IIIB 13.52 12.12 3 21303 34 64477392
Psychotic disorder 13.44 12.12 33 21273 34545 64442881
Sputum purulent 13.36 12.12 7 21299 1219 64476207
Nasopharyngitis 13.32 12.12 28 21278 196045 64281381
Full blood count abnormal 13.31 12.12 30 21276 29727 64447699
Hypoxia 13.25 12.12 61 21245 88088 64389338
Pre-eclampsia 13.02 12.12 13 21293 6218 64471208
Application site warmth 12.79 12.12 4 21302 181 64477245
Neuropathy peripheral 12.75 12.12 12 21294 117513 64359913
Ischaemic stroke 12.69 12.12 29 21277 29006 64448420
Pyrexia 12.56 12.12 121 21185 558523 63918903
Gastrointestinal disorder 12.55 12.12 7 21299 89702 64387724
Systemic lupus erythematosus 12.48 12.12 5 21301 77607 64399819
Injection site erythema 12.33 12.12 4 21302 70796 64406630
Hallucination, synaesthetic 12.29 12.12 3 21303 53 64477373
Anaphylactic reaction 12.22 12.12 50 21256 68614 64408812
Oedema mouth 12.20 12.12 9 21297 2864 64474562

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07BA01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in nicotine dependence
FDA CS M0014836 Nicotine
MeSH PA D018678 Cholinergic Agents
MeSH PA D018679 Cholinergic Agonists
MeSH PA D005731 Ganglionic Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018722 Nicotinic Agonists
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D000077444 Smoking Cessation Agents
FDA EPC N0000175706 Cholinergic Nicotinic Agonist
CHEBI has role CHEBI:22917 botanical insecticides
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:47958 muscarinic agonists
CHEBI has role CHEBI:49110 peripheral nervous system drugs
CHEBI has role CHEBI:50846 Immunologic factor
CHEBI has role CHEBI:50905 teratogeno
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:52290 mitogens
CHEBI has role CHEBI:59163 biological marker
CHEBI has role CHEBI:76924 plant metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nicotine dependence indication 56294008 DOID:0050742
Smoking cessation assistance indication 384742004
Pellagra indication 418186002 DOID:8457
Niacin deficiency indication 418279001
Nicotine Withdrawal Symptoms indication
Hyperlipidemia off-label use 55822004 DOID:1168
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Temporomandibular joint disorder contraindication 41888000
Low blood pressure contraindication 45007003
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Prinzmetal angina contraindication 87343002
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Pheochromocytoma contraindication 302835009
Acute coronary syndrome contraindication 394659003
Pharyngitis contraindication 405737000 DOID:2275
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000
Life-Threatening Cardiac Arrhythmias contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.05 Basic
pKa2 3.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel AGONIST Ki 8.56 WOMBAT-PK CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 5.39 WOMBAT-PK
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 7.40 WOMBAT-PK
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.80 IUPHAR
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 5.95 WOMBAT-PK
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 7.85 WOMBAT-PK
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 7.64 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 4.15 CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel Ki 5.83 CHEMBL
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel IC50 7.07 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.68 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel IC50 7.35 CHEMBL
Cytochrome P450 2A6 Enzyme IC50 5.36 WOMBAT-PK
Acetylcholine-binding protein Unclassified Ki 7.20 CHEMBL
Acetylcholine receptor subunit delta Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 9.03 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.89 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.61 CHEMBL
Neuronal acetylcholine receptor subunit alpha-9 Ion channel Kd 8.30 CHEMBL
Neuronal acetylcholine receptor subunit beta-4 Ion channel Ki 7.14 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel Ki 7.33 CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel Ki 7.92 CHEMBL
Soluble acetylcholine receptor Unclassified Ki 7.52 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.64 CHEMBL
Lycopene cyclase Enzyme IC50 5.32 CHEMBL
Nicotinic acetylcholine receptor alpha 5 subunit Ion channel Ki 5.61 CHEMBL
Acetylcholine receptor subunit beta-like 2 Ion channel Ki 5.57 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 8.72 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel IC50 8.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 6.70 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Kd 9.40 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor Ion channel Kd 11 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Acetylcholine receptor Ion channel Ki 5.20 CHEMBL
Muscarinic acetylcholine receptor GPCR IC50 4.55 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel EC50 5 CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 7.40 IUPHAR

External reference:

IDSource
4020286 VUID
N0000148163 NUI
D03365 KEGG_DRUG
65-31-6 SECONDARY_CAS_RN
4018610 VANDF
4020286 VANDF
C0028040 UMLSCUI
CHEBI:17688 CHEBI
NCT PDB_CHEM_ID
CHEMBL3 ChEMBL_ID
DB00184 DRUGBANK_ID
D009538 MESH_DESCRIPTOR_UI
89594 PUBCHEM_CID
2585 IUPHAR_LIGAND_ID
6M3C89ZY6R UNII
1306106 RXNORM
11529 MMSL
5173 MMSL
5174 MMSL
72003 MMSL
d00316 MMSL
001770 NDDF
003575 NDDF
323283001 SNOMEDCT_US
68540007 SNOMEDCT_US
77544001 SNOMEDCT_US
D061485 MESH_DESCRIPTOR_UI
CHEMBL1201536 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5400 INHALANT 4 mg RESPIRATORY (INHALATION) NDA 29 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0053 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotinemint HUMAN OTC DRUG LABEL 1 0113-0206 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0344 LOZENGE 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0422 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0456 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0532 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0704 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0713 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0734 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0749 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0761 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0854 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-0873 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0957 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-1125 LOZENGE 2 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1190 LOZENGE 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1352 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7007 LOZENGE 4 mg ORAL ANDA 14 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7008 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7124 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7190 LOZENGE 4 mg ORAL ANDA 15 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7201 LOZENGE 2 mg ORAL ANDA 14 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7203 LOZENGE 4 mg ORAL ANDA 14 sections